Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH

被引:52
作者
Svegliati-Baroni, Gianluca [1 ,2 ]
Patricio, Barbara [3 ,4 ,5 ]
Lioci, Gessica [6 ]
Macedo, Maria Paula [5 ,7 ,8 ]
Gastaldelli, Amalia [3 ,4 ]
机构
[1] Osped Riuniti Ancona, Liver Injury & Transplant Unit, I-60020 Ancona, Italy
[2] Polytech Univ Marche, Obes Ctr, I-60121 Ancona, Italy
[3] CNR, Cardiometab Risk Unit, Inst Clin Physiol, I-56124 Pisa, Italy
[4] St Anna Sch Adv Studies, Inst Life Sci, I-56127 Pisa, Italy
[5] APDP Diabet Portugal Educ & Res Ctr APDP ERC, P-1250189 Lisbon, Portugal
[6] Polytech Univ Marche, Dept Gastroenterol, I-60121 Ancona, Italy
[7] Univ Nova Lisboa, Fac Ciencias Med, CEDOC, NOVA Med Sch, P-1150082 Lisbon, Portugal
[8] Univ Aveiro, Inst Biomed iBiMED, Dept Med Sci, P-3810193 Aveiro, Portugal
基金
欧盟地平线“2020”;
关键词
non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; type-2; diabetes; gut-pancreas-liver axis; incretins; lipid metabolism; glucose metabolism; NONALCOHOLIC FATTY LIVER; GLUCAGON-LIKE PEPTIDE-1; GASTRIC-INHIBITORY POLYPEPTIDE; TYPE-2; DIABETES-MELLITUS; BETA-CELL FUNCTION; METFORMIN-TREATED PATIENTS; COTRANSPORTER; INHIBITOR; PLACEBO-CONTROLLED TRIAL; GLP-1 RECEPTOR AGONIST; DIET-INDUCED OBESITY;
D O I
10.3390/ijms21165820
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) represents the most common form of chronic liver disease worldwide. Due to its association with obesity and diabetes and the fall in hepatitis C virus morbidity, cirrhosis in NAFLD is becoming the most frequent indication to liver transplantation, but the pathogenetic mechanisms are still not completely understood. The so-called gut-liver axis has gained enormous interest when data showed that its alteration can lead to NAFLD development and might favor the occurrence of non-alcoholic steatohepatitis (NASH). Moreover, several therapeutic approaches targeting the gut-pancreas-liver axis, e.g., incretins, showed promising results in NASH treatment. In this review, we describe the role of incretin hormones in NAFLD/NASH pathogenesis and treatment and how metagenomic/metabolomic alterations in the gut microbiota can lead to NASH in the presence of gut barrier modifications favoring the passage of bacteria or bacterial products in the portal circulation, i.e., bacterial translocation.
引用
收藏
页码:1 / 39
页数:39
相关论文
共 313 条
[121]   Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes [J].
Heise, T. ;
Morrow, L. ;
Hompesch, M. ;
Haering, H. -U. ;
Kapitza, C. ;
Abt, M. ;
Ramsauer, M. ;
Magnone, M. -C. ;
Fuerst-Recktenwald, S. .
DIABETES OBESITY & METABOLISM, 2014, 16 (11) :1070-1077
[122]   Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity [J].
Henao-Mejia, Jorge ;
Elinav, Eran ;
Jin, Chengcheng ;
Hao, Liming ;
Mehal, Wajahat Z. ;
Strowig, Till ;
Thaiss, Christoph A. ;
Kau, Andrew L. ;
Eisenbarth, Stephanie C. ;
Jurczak, Michael J. ;
Camporez, Joao-Paulo ;
Shulman, Gerald I. ;
Gordon, Jeffrey I. ;
Hoffman, Hal M. ;
Flavell, Richard A. .
NATURE, 2012, 482 (7384) :179-U67
[123]   Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates [J].
Henderson, S. J. ;
Konkar, A. ;
Hornigold, D. C. ;
Trevaskis, J. L. ;
Jackson, R. ;
Fritsch Fredin, M. ;
Jansson-Loefmark, R. ;
Naylor, J. ;
Rossi, A. ;
Bednarek, M. A. ;
Bhagroo, N. ;
Salari, H. ;
Will, S. ;
Oldham, S. ;
Hansen, G. ;
Feigh, M. ;
Klein, T. ;
Grimsby, J. ;
Maguire, S. ;
Jermutus, L. ;
Rondinone, C. M. ;
Coghlan, M. P. .
DIABETES OBESITY & METABOLISM, 2016, 18 (12) :1176-1190
[124]   Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial [J].
Hermansen, K. ;
Baekdal, T. A. ;
During, M. ;
Pietraszek, A. ;
Mortensen, L. S. ;
Jorgensen, H. ;
Flint, A. .
DIABETES OBESITY & METABOLISM, 2013, 15 (11) :1040-1048
[125]   GLUCAGON-LIKE PEPTIDE-1 AND GLUCOSE-DEPENDENT INSULIN-RELEASING POLYPEPTIDE PLASMA-LEVELS IN RESPONSE TO NUTRIENTS [J].
HERRMANN, C ;
GOKE, R ;
RICHTER, G ;
FEHMANN, HC ;
ARNOLD, R ;
GOKE, B .
DIGESTION, 1995, 56 (02) :117-126
[126]  
Hershkovitz O., 2013, P END SOC 95 ANN M E
[127]   Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial [J].
Hirschfield, Gideon M. ;
Chazouilleres, Olivier ;
Drenth, Joost P. ;
Thorburn, Douglas ;
Harrison, Stephen A. ;
Landis, Charles S. ;
Mayo, Marlyn J. ;
Muir, Andrew J. ;
Trotter, James F. ;
Leeming, Diana J. ;
Karsdal, Morten A. ;
Jaros, Mark J. ;
Ling, Lei ;
Kim, Kathline H. ;
Rossi, Stephen J. ;
Somaratne, Ransi M. ;
DePaoli, Alex M. ;
Beuers, Ulrich .
JOURNAL OF HEPATOLOGY, 2019, 70 (03) :483-493
[128]   The incretin system in healthy humans: The role of GIP and GLP-1 [J].
Hoist, Jens Juul .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2019, 96 :46-55
[129]   Glucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture, 2005 [J].
Holst, JJ .
DIABETOLOGIA, 2006, 49 (02) :253-260
[130]   Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women [J].
Hoyles, Lesley ;
Fernandez-Real, Jose-Manuel ;
Federici, Massimo ;
Serino, Matteo ;
Abbott, James ;
Charpentier, Julie ;
Heymes, Christophe ;
Latorre Luque, Jessica ;
Anthony, Elodie ;
Barton, Richard H. ;
Chilloux, Julien ;
Myridakis, Antonis ;
Martinez-Gili, Laura ;
Maria Moreno-Navarrete, Jose ;
Benhamed, Fadila ;
Azalbert, Vincent ;
Blasco-Baque, Vincent ;
Puig, Josep ;
Xifra, Gemma ;
Ricart, Wifredo ;
Tomlinson, Christopher ;
Woodbridge, Mark ;
Cardellini, Marina ;
Davato, Francesca ;
Cardolini, Iris ;
Porzio, Ottavia ;
Gentileschi, Paolo ;
Lopez, Frederic ;
Foufelle, Fabienne ;
Butcher, Sarah A. ;
Holmes, Elaine ;
Nicholson, Jeremy K. ;
Postic, Catherine ;
Burcelin, Remy ;
Dumas, Marc-Emmanuel .
NATURE MEDICINE, 2018, 24 (07) :1070-+